Mainboard · BSE and NSEDraft filed
Integris Medtech Limited IPO: dates, price band, lot size, objects of the issue
Get updates on this IPO
Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.Dates, allotment, listing and analyst views. Stop anytime.
By continuing you agree to the Terms and Privacy policy
Key facts
- Price band
- Not announced
- Lot size
- Not announced
- Lot amount at the upper band
- Not announced
- Issue size at the upper band
- Not announced
- Bid dates
- Not announced
- Listing date
- Not announced
- Proposed exchanges
- BSE and NSE
Timeline (IST)
- Draft filedWed 15 Oct 2025 confirmedDRHP dated Thu 9 Oct 2025
- OpensDates to be announced
- ClosesDates to be announced
- AllotmentDates to be announced
- Refund and unblockDates to be announced
- ListingDates to be announced
Objects of the issue
| Object | Amount |
|---|---|
| Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: | ₹696.39 crore |
| General corporate purposes | Not stated in the draft |
| Total | Not stated in the draft |
The offer for sale goes to the selling shareholders, not the company. DRHP dated Thu 9 Oct 2025, page 122
Company and promoters
As described in the DRHP
This portfolio includes cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. We operate manufacturing facilities in India, Germany, and the Netherlands, and work with global manufacturers supporting a portfolio of medical devices and laboratory solutions sold in more than 65 countries, as of June 30, 2025.
DRHP dated Thu 9 Oct 2025, page 21
Promoters
- Evercure Holdings Pte. Ltd.
- Medicore Holdings Pte. Ltd.
- 2 individual promoters
DRHP dated Thu 9 Oct 2025, page 21
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 84.04% | Not stated in the DRHP |
| Public | 15.96% | Not stated in the DRHP |
DRHP dated Thu 9 Oct 2025, page 115
Financials (restated)
| Item | three months period ended June 30, 2025 | Financial Year ended March 31, 2025 | Financial Year ended March 31, 2024 | Financial Year ended March 31, 2023 |
|---|---|---|---|---|
| Revenue from operations | ₹485.25 crore | ₹1,902.47 crore | ₹1,553.38 crore | ₹1,348.10 crore |
| Profit after tax | ₹267.57 crore | ₹70.68 crore | -₹4.88 crore | -₹40.54 crore |
| Net worth | ₹3,889.99 crore | ₹2,752.52 crore | ₹2,681.02 crore | ₹2,629.52 crore |
| Total borrowings | ₹793.42 crore | ₹1,729.46 crore | ₹813.10 crore | ₹556.54 crore |
DRHP dated Thu 9 Oct 2025, page 23
Who is selling in the offer for sale
| Selling shareholder | Type | Shares offered | Amount at the upper band |
|---|---|---|---|
| Evercure Holdings Pte. Ltd. | Company | 1,51,74,251 | Not announced |
| Individual shareholder | Individual | 32,50,140 | Not announced |
| Individual shareholder | Individual | 32,50,140 | Not announced |
| Total offer for sale | Not stated in the draft | ||
DRHP dated Thu 9 Oct 2025, page 1
Peer comparison (as in the DRHP)
| Particulars | Standalone/ Consolidated | Face value per equity share (₹) | Closing Price as on October 8, 2025 (₹) | P/E | Revenue from operations for fiscal 2025 (₹ in million) | EPS (Basic) (₹) | EPS (Diluted) (₹) | RoNW (%) | Net Asset Value per Equity Share (₹) |
|---|---|---|---|---|---|---|---|---|---|
| Our Company** | Consolidated | 1 | NA | NA*** | 19,024.66 | 5.82 | 5.73 | 1.84 | 316.09 |
| Poly Medicure Limited | Consolidated | 5 | 1,911.00 | 56.02 | 16,698.32 | 34.13 | 34.11 | 12.26 | 278.46 |
| Laxmi Dental Limited | Consolidated | 2 | 326.40 | 53.95 | 2,391.07 | 6.07 | 6.05 | 16.09 | 37.71 |
Reproduced from the DRHP dated Thu 9 Oct 2025, page 168; InsightPier adds no figures
Risk factors
91 total- The company had losses in Fiscal 2024 and Fiscal 2023, and its profit for the June 2025 quarter came mainly from a one-time accounting gain (DRHP page 39)
- Most revenue comes from outside India, which exposes the company to overseas economic, regulatory and operational risks (DRHP page 40)
- Growth has depended on acquisitions, and future deals may be hard to integrate or may not deliver the expected value (DRHP page 41)
- Delays or failures in getting or renewing regulatory approvals in India or abroad could stop the company selling its products (DRHP page 42)
- Product quality issues, recalls or safety alerts on its medical devices could disrupt operations and cause losses (DRHP page 43)